Nama's AI scorecard currently rates CG Oncology Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.

When does CGON report earnings?

CG Oncology's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.81.

What is the CGON price target?

The median analyst price target from 13 analysts is $90.00, with a range of $79.00 – $108.00.

Is CGON Shariah compliant?

Nama's AAOIFI-style screen reads CG Oncology as Not Shariah Compliant. At least one of the three ratios or the industry test failed.

Nama Insights

CG Oncology (CGON)

Healthcare · Biotechnology · NASDAQ

CG Oncology (CGON) is a Healthcare company in the Biotechnology industry. It has a market capitalization of $6.74B and a free-cash-flow yield of -2.2%. Over the most recent reported fiscal year, revenue grew 254.7%. Nama's AI scorecard rates it Sell, 2.3 out of 10. On 12-month momentum it ranks in the rising band of its market.

AI scorecard

Sell · 2.3/10

Clearly negative, short of the bottom band. As of Nov 7, 2026.

Momentum

Rising · +57.2% over 12 months ex. last

Second-best fifth of its market on the past year's move.

Shariah screen

Not Shariah Compliant

At least one of the three ratios or the industry test failed.

Off its high

-6.2%

How far the last close sits under the highest price of the past five years.

Market cap	$6.74B
Trailing P/E	—
Price / book	6.5
Price / sales	1085.6
FCF yield	-2.2%
Dividend yield	—
Gross margin	-85.2%
Operating margin	-4056.2%
Net margin	-3602.7%
Revenue growth (YoY)	+254.7%
Revenue growth (3-yr annual)	+176.6%
EPS growth (YoY)	—
FCF/share growth (YoY)	—
Beta	0.3
Exchange	NASDAQ
Sector	Healthcare
Industry	Biotechnology

CGON earnings

Next report: Nov 9, 2026 (Q3 2026, EPS estimate -$0.81). Beat the EPS estimate in 1 of 4 recent quarters.

Quarter	Reported	EPS	Estimate	Surprise	Revenue
Q2 2026	Aug 6, 2026	-$0.90	-$0.64	-40.6%	$1.16M
Q1 2026	May 8, 2026	-$0.71	-$0.54	-31.5%	$1.08M
Q4 2025	Feb 27, 2026	-$0.51	-$0.58	+12.1%	$2.32M
Q3 2025	Nov 14, 2025	-$0.57	-$0.55	-3.6%	$1.67M

CGON analyst price target

Median target $90.00 from 13 analysts, ranging $79.00 – $108.00.

Biotechnology peers

Ticker	Company	Market cap	P/E
VRTX	Vertex Pharmaceuticals	$138.71B	28.8
MRNA	Moderna	$101.48B	—
REGN	Regeneron Pharmaceuticals	$93.55B	16.4
ARGX	argenx	$58.31B	32.4
ONC	BeOne Medicines	$46.30B	51.7
RVMD	Revolution Medicines	$41.59B	—
RPRX	Royalty Pharma	$38.70B	12.7
GMAB	Genmab A/S	$32.98B	38.9

Explore live CGON data on Nama Insights →

CGON FAQ

Is CGON a buy?: Nama's AI scorecard currently rates CG Oncology Sell (2.3 out of 10), a call computed from its profitability, cash generation, growth, valuation and balance sheet. It is a research reading, not investment advice.
When does CGON report earnings?: CG Oncology's next scheduled report is on Nov 9, 2026. Analysts expect EPS of -$0.81.
What is the CGON price target?: The median analyst price target from 13 analysts is $90.00, with a range of $79.00 – $108.00.
Is CGON Shariah compliant?: Nama's AAOIFI-style screen reads CG Oncology as Not Shariah Compliant. At least one of the three ratios or the industry test failed.